Clopidogrel FDA Link

A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.

Also Known As:

Plavix; Clopidogrel Besilate; Clopidogrel Besylate; Clopidogrel Bisulfate; Clopidogrel Hydrochloride; Clopidogrel Napadisilate; Clopidogrel Sandoz; Clopidogrel, (+)(S)-isomer; Clopidogrel-Mepha; Iscover; PCR 4099; PCR-4099; SC 25989C; SC 25990C; SR 25989; Clopidogrel Mepha; Methyl 2- (2- chlorophenyl)- 2- (4,5,6,7- tetrahydrothieno(3,2- c)pyridin- 5- yl)acetate

Organic Chemicals: 140
- Sulfur Compounds: 283
  - Thiophenes: 266
    - Thienopyridines: 213
      - Ticlopidine: 1145
        Clopidogrel: 7724
Heterocyclic Compounds: 207
- 1-Ring Heterocyclic Compounds
  - Thiophenes: 266
    - Thienopyridines: 213
      - Ticlopidine: 1145
        Clopidogrel: 7724
  - Pyridines: 91
    - Thienopyridines: 213
      - Ticlopidine: 1145
        Clopidogrel: 7724
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Thienopyridines: 213
      - Ticlopidine: 1145
        Clopidogrel: 7724

Daniel Baro Selected Research

Daniel Baro Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure